Preferred Label : teriparatide;

MeSH definition : A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995);

MeSH synonym : human parathyroid hormone (1-34); hpth (1-34);

CISMeF synonym : 99294-94-7 (Teriparatide acetate); aventis brand of teriparatide; teriparatide aventis brand; lilly brand of teriparatide; teriparatide lilly brand;

MeSH hyponym : parathar; teriparatide acetate; forteo;

MeSH Related Number : teriparatide acetate; 52232-67-4 (Teriparatide); 9959P4V12N;

Registry Number MeSH : 52232-67-4;

Related CAS MeSH : 9959P4V12N (Teriparatide acetate);

Wikipedia link : https://en.wikipedia.org/wiki/Teriparatide;

Is substance : O;

UNII : 10T9CSU89I;

Details


Main resources

You can consult :

A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

http://www.has-sante.fr/portail/jcms/c_1751307/fr/les-medicaments-de-losteoporose
2023
false
true
false
France
French
bone density conservation agents
osteoporosis
treatment outcome
alendronic acid
alendronate
guidelines for drug use
zoledronic acid
administration, oral
risedronic acid
denosumab
Raloxifene Hydrochloride
strontium ranelate
strontium ranelate
teriparatide
teriparatide
spinal fractures
hip fractures
costs and cost analysis
bone density conservation agents
drug costs
bone density
risk
osteoporosis, postmenopausal
adrenal cortex hormones
osteoporosis
osteoporotic fractures
alendronic acid and colecalciferol
drugs, generic
infusions, intravenous
risedronic acid, calcium and colecalciferol, sequential
injections, subcutaneous
raloxifene
algorithms
Adrenocortical steroid therapy
corticosteroid therapy
Risedronic Acid
Denosumab
diphosphonates
imidazoles
organometallic compounds
thiophenes
Zoledronic Acid

---
https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
teriparatide
teriparatide
teriparatide
bone density conservation agents
bone density conservation agents
adult
osteoporosis
osteoporosis, postmenopausal
osteoporotic fractures
injections, subcutaneous
drug interactions
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/sondelbay-0
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
teriparatide
teriparatide
teriparatide
biosimilar pharmaceuticals
osteoporotic fractures
osteoporosis
osteoporosis, postmenopausal
male osteoporosis
drug approval
europe
bone density conservation agents
bone density conservation agents
Osteoporosis caused by corticosteroid (disorder)
injections, subcutaneous
Calcium-Regulating Hormones and Agents
Calcium-Regulating Hormones and Agents
pregnancy
breast feeding
drug interactions
product surveillance, postmarketing
drug storage
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/livogiva
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
teriparatide
teriparatide
biosimilar pharmaceuticals
osteoporosis, postmenopausal
osteoporosis
osteoporotic fractures
male osteoporosis
Osteoporosis caused by corticosteroid (disorder)
osteoporosis
glucocorticoids
injections, subcutaneous
bone density conservation agents
bone density conservation agents
teriparatide
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/qutavina
2021
false
false
false
Netherlands
French
English
Safety-Based drug withdrawals
teriparatide
drug evaluation
summary of product characteristics
teriparatide
treatment outcome
syndication feed
package leaflet

---
https://www.has-sante.fr/jcms/p_3159915/fr/movymia
2020
false
false
false
France
teriparatide
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3182788/fr/terrosa
2020
false
false
false
France
teriparatide
biosimilar pharmaceuticals
evaluation of the transparency committee
teriparatide
insurance, health, reimbursement
treatment outcome
bone density conservation agents
osteoporosis, postmenopausal
male osteoporosis
osteoporotic fractures
spinal fractures
Osteoporosis caused by corticosteroid (disorder)
osteoporosis

---
https://www.has-sante.fr/portail/jcms/c_2906419/fr/movymia
2019
false
false
false
France
teriparatide
teriparatide
treatment outcome
insurance, health, reimbursement
osteoporosis
osteoporotic fractures
bone density conservation agents
bone density conservation agents
teriparatide
biosimilar pharmaceuticals
osteoporosis, postmenopausal
injections, subcutaneous
male osteoporosis
evaluation of the transparency committee

---
https://pharmacomedicale.org/medicaments/par-specialites/item/derives-de-la-parathormone
2017
false
false
false
France
osteoporosis
teriparatide
osteoporosis, postmenopausal
parathyroid hormone
drug information
parathyroid hormone

---
https://www.ema.europa.eu/medicines/human/EPAR/Movymia
2017
false
United Kingdom
French
English
syndication feed
biosimilar pharmaceuticals
male osteoporosis
europe
osteoporosis
osteoporosis
osteoporotic fractures
glucocorticoids
osteoporosis, postmenopausal
teriparatide
teriparatide
bone density conservation agents
bone density conservation agents
treatment outcome
drug approval
spinal fractures
injections, subcutaneous
drug interactions
drug evaluation, preclinical
drug storage
teriparatide
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/Terrosa
2017
false
United Kingdom
French
English
syndication feed
biosimilar pharmaceuticals
europe
male osteoporosis
osteoporosis
osteoporosis
osteoporotic fractures
glucocorticoids
osteoporosis, postmenopausal
teriparatide
teriparatide
bone density conservation agents
bone density conservation agents
treatment outcome
drug approval
spinal fractures
injections, subcutaneous
drug interactions
drug evaluation, preclinical
drug storage
teriparatide
drug evaluation
summary of product characteristics
package leaflet

---
Medikamentöse Osteoporose-therapie: Behandlungsdauer und Vorgehen nach Therapieende
https://medicalforum.ch/fr/detail/doi/fms.2017.03062/
10.4414/fms.2017.03062
2017
false
false
false
Switzerland
French
German
journal article
osteoporosis, postmenopausal
diphosphonates
bisphosphonates
Denosumab
practice guidelines as topic
denosumab
bone density conservation agents
rank ligand
comparative effectiveness research
teriparatide
teriparatide
Duration of treatment (qualifier value)
osteoporotic fractures
treatment outcome
spinal fractures
guidelines for drug use
bone density
risk
vitamin D
hip fractures
Rebound effect
Therapy cessation
Tumor Necrosis Factor Inhibitors

---
http://www.has-sante.fr/portail/jcms/c_1766733/fr/forsteo
http://www.has-sante.fr/portail/display.jsp?id=c_399963
2014
false
France
French
osteoporosis
Osteoporosis caused by corticosteroid (disorder)
corticosteroid therapy
injections, subcutaneous
pharmaceutical solutions
teriparatide
osteoporotic fractures
bone density conservation agents
osteoporosis, postmenopausal
treatment outcome
insurance, health, reimbursement
teriparatide
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Forsteo
2012
United Kingdom
French
English
syndication feed
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
osteoporosis
osteoporosis
osteoporotic fractures
glucocorticoids
osteoporosis, postmenopausal
teriparatide
teriparatide
bone density conservation agents
bone density conservation agents
treatment outcome
drug evaluation
drug approval
drug labeling
spinal fractures
injections, subcutaneous
drug interactions
drug evaluation, preclinical
drug storage
teriparatide
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-09/forsteo_ct_5572.pdf
http://www.has-sante.fr/portail/jcms/c_854109/forsteo
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-10/forsteo_-_ct-_6739.pdf
http://www.has-sante.fr/portail/jcms/c_697253/forsteo
2009
France
English
French
Adrenocortical steroid therapy
corticosteroid therapy
pharmaceutical solutions
teriparatide
osteoporosis
bone density conservation agents
osteoporosis
adrenal cortex hormones
fractures, bone
insurance, health, reimbursement
injections, subcutaneous
treatment outcome
teriparatide
osteoporosis, postmenopausal
evaluation of the transparency committee

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Forteo_SIO_July%2023_2009_f.pdf
2009
Canada
French
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
pharmaceutical solutions
injections, subcutaneous
randomized controlled trials as topic
treatment outcome
Cost-Benefit analysis
teriparatide
bone density conservation agents
insurance, health, reimbursement
canada
bone density conservation agents
teriparatide
glucocorticoids
osteoporosis
osteoporosis
teriparatide
drug evaluation

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-5200_forsteo_2008_03_28__17_10_59_920.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-06/forsteo_ct_5200.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_642553
2008
France
English
French
bone density conservation agents
injections, subcutaneous
pharmaceutical solutions
teriparatide
fractures, bone
osteoporosis
treatment outcome
insurance, health, reimbursement
teriparatide
evaluation of the transparency committee

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61122200
2008
France
French
injections, subcutaneous
teriparatide
pharmaceutical solutions
teriparatide
drug information

---
http://www.meddispar.fr/medicaments/3622162
2008
France
French
teriparatide
legislation, drug
bone density conservation agents
drug prescriptions
injections, subcutaneous
teriparatide
drug information

---
https://www.cadth.ca/sites/default/files/pdf/301_teriparatide_tr_appendices_f.pdf
https://www.cadth.ca/fr/analyse-clinique-et-economique-du-teriparatide-et-des-bisphosphonates-dans-le-traitement-de
2006
true
Canada
French
teriparatide
bone density conservation agents
diphosphonates
osteoporosis, postmenopausal
bisphosphonates
teriparatide
drug evaluation
economic evaluation

---
http://www.has-sante.fr/portail/display.jsp?id=c_460016
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct032662.pdf
2006
France
French
bone density conservation agents
teriparatide
osteoporosis, postmenopausal
injections, subcutaneous
spinal fractures
teriparatide
evaluation of the transparency committee
comparative study

---
https://www.cadth.ca/sites/default/files/pdf/275_teriparide_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/275_teriparide_cetap_e.pdf
2003
Canada
English
French
bone density conservation agents
teriparatide
canada
treatment outcome
united states
osteoporosis
fractures, bone
randomized controlled trials as topic
risk factors
teriparatide
drug evaluation

---
https://www.cadth.ca/sites/default/files/pdf/108_No44_teriparatide_edrug_f.pdf
2003
Canada
French
bone density conservation agents
teriparatide
osteoporosis
united states
controlled clinical trials as topic
canada
teriparatide
drug evaluation

---
Nous contacter.
02/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.